Purpose: To evaluate using phantom study the average glandular dose (AGD) and image quality in breast tomosynthesis. Materials and methods: The study was performed with a full-field digital mammography system (Mammomat Inspiration ® , Siemens, Erlangen, Germany) combined with tomosynthesis equipment (3D). For AGD evaluation, polymethyl methacrylate (PMMA) plates and a dosimeter were used to directly measure the absorbed doses in 2D and in 3D. The doses were then compared to the doses displayed on the equipment using the Mann-Whitney test. Three phantoms, accredited for 2D digital mammography (MTM 100, ACR RMI 156, BR3D), were imaged three times in 2D then in 3D. For each acquisition, the AGD was recorded. For image quality assessment, scores, defined by the rate of visible inserts, obtained for each acquisition both in 2D and in 3D, and for each phantom, were compared (Kruskall-Wallis and post-hoc Dunn tests). Results: There was no significant difference between the measured and displayed AGD, both in 2D and in 3D imaging (P > 0.05). With identical acquisition parameters, AGD were significantly greater in 3D than in 2D P < 0.01). For phantoms MTM 100 and ACR RMI 156, there was no significant difference between the rate of visible inserts in 2D and in 3D (P = 0.06 and P = 0.36, respectively). However for phantom BR3D, the rate was significantly higher in 3D than in 2D (P < 0.0001). Conclusion: Doses are significantly greater in 3D than in 2D. With tomosynthesis, out of the three phantoms tested, only phantom BR3D showed a higher rate of visible inserts.
By comparison with screen-film radiography, digital mammography improves breast cancer screening [1] [2] [3] , reduces average glandular dose [2] [3] [4] [5] by about 22% [4] and makes it possible to add tomosynthesis in routine use [6] . The combination of tomosynthesis with digital mammography increases diagnostic accuracy [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] and reduces recall rates by 30 to 40% [8, 9] . In the United States, tomosynthesis was approved by the Food and Drug Administration in 2011 [16] . However, recent articles have reported that the AGD per view is higher in tomosynthesis mode than with mammography alone [13, 15, 17] . Therefore, reducing the dose is essential to validate a possible use of tomosynthesis in screening programs. In addition, the absorbed dose in tomosynthesis should be assessed simultaneously with image quality, like is currently done for 2D mammography breast cancer screening programs. In France, regulatory quality control testing of digital mammography screening is done with phantoms in order to obtain reproducible testing, and thereby a long-term follow-up of mammography systems. In France, only phantom MTM 100 (Meditest, France) is used in mammography screening programs, but tomosynthesis is not covered [18] . To the best of our knowledge, there is not one specific phantom for tomosynthesis acquisitions, unlike for 2D mammography. However, several phantoms are on the market and could be adapted to assess breast tomosynthesis reconstructions.
The goal of this study was to evaluate the average glandular dose (AGD) and the quality of the images obtained by tomosynthesis using the phantoms currently available.
Materials and methods

Tomosynthesis
All the images were acquired with the Mammomat Inspiration ® mammograph (Siemens, Erlangen, Germany).
The 3D tomosynthesis acquisition parameters were the following: an overall angle of 50 • , with the X-ray tube rotating 25 • in both directions from the target by 2-degree increments to obtain 26 projection views. A reconstruction algorithm (Equalizing Filtered Back Projection) was applied to obtain 1-mm slices.
Evaluation of AGD in 2D and 3D imaging on polymethyl metacrylate (PMMA) plates
The AGD was evaluated in 2D and 3D imaging, on PMMA plates of varying thickness. Five images were acquired in 2D then in 3D with PMMA placed on the detector plate while the thickness varied from 20 to 60 mm, by 10-mm increments (Fig. 1) . The values of kV, mAs and AGD displayed by the mammography system were recorded.
Using a Piranha dosimeter (RTI electronics AB, Sweden), the AGD was measured for 2D (noted AGD) and for 3D (noted AGD T ). The AGD was calculated based on the entrance surface air kerma (ESAK). Acquisitions were obtained in manual mode, with parameters selected so as to be as close as possible to those used in clinical practice. The detector was placed on the compression paddle so as not to affect the AGD delivered during exposure (Fig. 2 ). 
2D measurement of AGD
The AGD in 2D imaging is obtained by formula (1):
with g the conversion factor to calculate the AGD based on the ESAK for a medium dense breast (50% glandularity); with c the correction factor for the density of the breast; and with s the correction factor for the X-ray spectrum (anode/filter combination). g and c values are obtained, if necessary by linear interpolation, from values calculated by Dance et al. [19] [20] [21] .
3D measurement of AGD
AGD was measured in tomosynthesis imaging (noted AGD T ), also with a Piranha detector. Like for 2D, the value was also calculated based on the ESAK and noted ESAK T , but with 3D acquisition parameters dependent on the corresponding PMMA thickness. To estimate the AGD T obtained in tomosynthesis, we used the tables of Dance et al. [22] . Because of the angular dependence of the detector, the AGD T could only be measured in fixed mode with the detector placed on the compression paddle during exposure, when the incidence of the X-ray tube was fixed at 0 • position. The X-ray tube remained stationary. The Piranha detector was not moved between exposures. Let T be the correction factor of the X-ray tube incidence during exposure. This T value is based on the thickness of the breast phantom and the tables of Dance et al. [22] . The AGD T for the tomosynthesis, based on formula (1), was obtained by formula (2):
Breast equivalent phantoms
The following three phantoms were used:
• phantom MTM 100 (Meditest, France) ( Fig. 3 ). This phantom has characteristics that meet the requirements of the French regulatory authorities (Agence Nationale de Sécurité du Médicament et des produits de santé, ANSM) and is mandatory in France for quality control testing [1]; • phantom BR3D (Meditest, France) ( Fig. 4 ). This phantom has not been approved for the French regulatory quality control testing, but was designed for quality control testing in tomosynthesis and CT scan; • phantom ACR RMI 156 (Siemens, Erlangen, Germany) ( Fig. 5 ). This phantom is used in the United States and is accredited by the American College of Radiology for quality controls in 2D mammography.
Evaluation of AGD in 2D and 3D imaging on breast phantoms
The three phantoms, MTM 100, BR3D and ACR RMI 156, were imaged in 2D and in 3D. In addition, phantom BR3D was imaged over a thickness range of 1 to 6 slices; the slice containing the inserts was successively placed from top to bottom. For each phantom, two types of acquisition modes, Opdose and AEC (Automatic Exposure Control), were used, in 2D, then in 3D imaging. The Opdose mode works automatically with the compression system; it selects the acquisition parameters according to the progressive compression resistance and to the thickness of the imaged target. The AEC mode is semi-automatic and has 3 settings: low dose (-20%), normal dose and high dose (+20%). Thus, altogether, four acquisition modes were used: Opdose, low dose AEC, normal dose AEC and high dose AEC. Table 1 shows the different acquisition parameters. Displayed doses were recorded for each phantom and each acquisition mode, after both 2D and 3D imaging. The doses for each acquisition parameter were only recorded once, because the reproducibility of the displayed doses and the X-ray tube had been previously verified by the medical physicist (unpublished personal 
Quality control testing of 2D and 3D imaging on breast phantoms
For the quality control testing, acquisitions were obtained only in AEC mode (normal, low and high dose). The decision to select only the AEC mode was twofold: first, the doses delivered in Opdose and normal dose AEC are identical -except when the thickness of the phantom is less or equal to 1 cm, and secondly because the AEC mode is the only mode that provides 3 settings. For the quality control, all the acquisitions in 2D, and then in 3D mode, were repeated 3 times, i.e. 6 series of acquisitions for each phantom. For phantom BR3D, 6 series of acquisitions were performed for each position of the slice containing the inserts, with each time a different phantom thickness (1 to 6 slices). 3D imaging of phantom BR3D, with only one slice, was technically impossible in normal and low dose mode. Altogether, 136 series of image acquisitions on breast phantom were obtained, and this, for each AEC setting, normal dose, low dose and high dose.
Assessment of image quality in 2D and 3D imaging on breast phantoms
Images were read on a 21-inch-HD screen (5 million pixels, Syngo Mammo Report, Siemens, Erlangen, Germany) by two senior radiologists specialized in senology (THD and EM) and one junior reader (IF). Readings were independently performed, at different times of the day, images were shown in a random order and results represent the mean scores of each reader. None of the readers had been specifically trained. Each reader counted the number of masses, fibers and clusters of microcalcifications on each view and compared the visible inserts to the total number of inserts. A partially visible insert was scored 0.5. Since the three phantoms contained a different number of inserts, results were Table 2 Comparison between measured and displayed AGD in Opdose mode, with varying thickness of PMMA plates. The measured AGD was significantly higher than the displayed AGD, but with a difference smaller than 20.91%. For all acquisitions, AGD in 3D were 1.76 to 2.16 times higher than in 2D. 
PMMA
Results
Dosimetry Table 2 shows the AGD values measured in 2D and in 3D with PMMA plates. Measured and displayed values of AGD were not significantly different, both in 2D and in 3D (P > 0.05). The displayed AGD systematically underestimated the dose by 6.2 to 20.9%. The doses obtained in 2D and in 3D on breast phantoms, for each acquisition mode (Opdose, low, normal and high dose) are shown in Table 3 . In identical acquisition mode, the displayed AGD in 3D were significantly higher than all the AGD obtained in 2D (P < 0.01). The displayed AGD obtained in 3D was 1.75 to 2.15 times higher than in 2D on PMMA plate and 1.5 (low dose AEC phantom ACR RMI 156) to 2.75 times higher (high dose AEC mode, phantom BR3D 1 slice) than in 2D (Tables 2 and 3) , with equivalent mode.
Comparison between quality scores based on delivered dose
For each phantom, no significant difference was observed between the scores obtained in low dose, normal dose and high dose AEC mode (P = 0.58).
Comparison between quality scores in 2D and 3D for each phantom
For phantoms MTM 100 and ACR RMI 156, no significant difference was observed between the rates of visible inserts in 2D and in 3D at equivalent dose (P = 0.06 and P = 0.36, respectively) ( Fig. 6 ). However, with phantom BR3D, whatever the thickness and the location of the inserts, the rate was significantly higher in 3D than in 2D imaging (P < 0.0001) ( Table 4 ) (Fig. 6 ). The increase in the rate of visible inserts in 3D was higher for masses and fibres than for microcalcifications. 
Discussion
The results obtained in this study confirm that the dose levels delivered with tomosynthesis are about twice those of 2D. Average doses in 2D ranged between 0.8 and 1.14PmGy, which is below the diagnostic reference level (DRL) of 1.8 mGy [23] for high-field digital mammography. In 3D imaging, there is no DRL. If we compare the delivered dose in 3D to the 2D DRL, it only exceeds by 10% the 2D reference level. Moreover, the results confirm that the displayed dose after each acquisition correlates with the measured dose, with a non-significant discrepancy, lower than the specifications of the manufacturer (30% discrepancy). It should however be noted that the displayed doses systematically underestimated the measured doses.
Routine use of tomosynthesis is recent, and, to the best of our knowledge, only few studies have analyzed the doses absorbed in tomosynthesis in comparison to 2D mammography. On the other hand, the existing studies have shown very variable results with additional doses delivered in tomosynthesis from +8% to +2.24 times the dose delivered in 2D [13, 15, 17] . In our study, the parameters analyzed are those used in clinical setting. This study differentiates the scores obtained in the 3 different AEC acquisition modes, and does not show a significant difference in the quality scores on phantoms for the three modes. This suggests that the low dose should be preferred.
Image quality analysis of tomosynthesis confirms that 3D imaging significantly improves the detection of abnormalities [13] [14] [15] . For phantom BR3D, the improved scores obtained in 3D compared to 2D are similar to those reported in the literature [14, 15] . On the other hand, the score differences for phantoms MTM 100 and ACR RMI 156 are low, which was to be expected since both phantoms were developed for 2D mammography quality control.
The main limitation of the different and numerous breast phantoms used in studies is their uniformity. The mammary gland is difficult to reproduce: it is complex and the proportion of the elements contained in it is variable [24] [25] [26] [27] [28] [29] . However, the improvement of abnormality detection in 3D imaging varies with the proportions of glandular and adipose tissue. Phantom BR3D used in this study was imaged with different theoretical breast thickness, by varying the number of slices used, and with different positions of the slice containing the inserts. In our study on phantom in 3D imaging, the detection of microcalcifications was not as clearly improved as for masses and fibers. This is in agreement with the findings reported in the literature [8] [9] [10] 12, 14] . Detection of microcalcifications is essential since intraductal carcinoma (CIC) detected only through microcalcifications represent 19% of the cancers screened [30, 31] . But 3D allows radiologists to use methods, such as the maximum intensity projection (MIP), specific to multislice imaging, to detect and analyze fine structures, such as microcalcifications [8, 32] . This has not been assessed in our study.
Also, we did not compare 3D and 2D scores for tomosynthesis in Combo mode. This mode, a combined 3D-2D mode is provided by the manufacturer of the mammography system. This mode delivers a lower dose than when 3D tomosynthesis is added to a 2D acquisition. The reason for this absence is because we aimed at strictly comparing 2D and 3D acquisitions.
Other methods to lower doses have been described and have not been assessed here, such as tomosynthesis only, the addition of only one incidence in tomosynthesis [9, 33] , or a synthetic 2D image reconstruction from a 3D acquisition, which seems promising in terms of abnormality detection [34, 35] .
In conclusion, our results on phantoms confirm that doses delivered in 3D are significantly higher than those delivered in 2D and that currently available phantoms are not suitable for image quality control in tomosynthesis. To integrate tomosynthesis in breast cancer screening programs, we need to develop suitable phantoms and reading tables.
